Exelixis Inc EXEL

US Biotechnology

$71.74 ▲ +3.12% (+$2.17)

Open $70.21

Prev Close $69.57

Day Range $69.39 – $72.15

52W Range $39.71 – $73.69

Market Cap $17.51B

P/E (TTM) 19.41

Beta 0.41

EPS (TTM) $3.34

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2000-04-11
Shares Out.	244,010,000
Website	exelixis.com/ ↗
Phone	13026587581
Employees	1,077
Revenue	$658.7M
Gross Profit	$632.5M
Net Income	$218.1M
Free Cash Flow	$1.16B
Total Assets	$2.51B
Total Liabilities	$679.7M
Equity	$1.83B

About Exelixis Inc

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Inc is a publicly traded company under the ticker symbol EXEL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.